Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials
Brexpiprazole is a new atypical antipsychotic for schizophrenia management and as adjunct in major depressive disorder (MDD). We searched randomized controlled trials (RCT) to review brexpiprazole efficacy and tolerability in acute management of schizophrenia and MDD using PubMed, EUDRACT, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials. A meta-analysis was conducted using the identified 14 RCT to assess its efficacy using positive and negative syndrome scale (PANSS), clinical global impressions – severity of illness (CGI-S), personal and social performance scale (PSP), Montgomery–Ås...
Source: International Clinical Psychopharmacology - March 28, 2020 Category: Psychiatry Tags: Review Articles Source Type: research

[Psychiatric and psychological support for an adolescent woman with chromosome 22 deletion syndrome and intellectual disability: a good outcome].
CONCLUSIONS: There was no transition to psychosis in the follow-up; OCD and trichotillomania persists, probably related to neurodevelopmental alterations, that are difficult to be modified. In 22q11.2DS patients, standard non-pharmacological treatment strategies (CBT) are difficult to apply, but in the present case the combination of pharmacological and psychoeducational psychological treatment was effective, both for the reduction of symptoms and for the acceptance of ID by patient and family. PMID: 32202548 [PubMed - in process] (Source: Rivista di Psichiatria)
Source: Rivista di Psichiatria - March 25, 2020 Category: Psychiatry Tags: Riv Psichiatr Source Type: research

Safety and Tolerability of Antipsychotic Drugs in Pediatric Patients: Data From a 1-Year Naturalistic Study
Background: Antipsychotic drugs (APs) are increasingly used to treat a variety of psychiatric disorders in children and adolescents. However, their safety and tolerability profiles, when used in a developmental age context, show different characteristics from the ones observed in adult patients. Treatment with APs in pediatric patients is often long-term. However, the tolerability data regarding these patients mostly derive from short-term studies.Methods: Starting from April 2017, for a 1-year period, patients between 4 and 18 years of age followed by five units of developmental age neuropsychiatry, who initiated a treatm...
Source: Frontiers in Psychiatry - March 24, 2020 Category: Psychiatry Source Type: research

Association Between Antipsychotics and Osteoporosis Based on Real-World Data.
Conclusion and Relevance: Real-world data show no association between antipsychotic use and the onset of osteoporosis. Further pharmacoepidemiological studies are needed for causality assessment. PMID: 32186394 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - March 18, 2020 Category: Drugs & Pharmacology Authors: Yokoyama S, Wakamoto S, Tanaka Y, Nakagawa C, Hosomi K, Takada M Tags: Ann Pharmacother Source Type: research

Update on the Treatment of Tics in Tourette Syndrome and Other Chronic Tic Disorders
AbstractPurpose of reviewThis review presents a critical appraisal of current therapeutic strategies for tics in patients with Tourette syndrome (TS) and other chronic tic disorders. We discuss the most recent evidence to support behavioural/psychosocial, pharmacological and surgical interventions in patients with tics and summarize existing recommendations about treatment selection. We also indicate the main knowledge gaps regarding efficacy, safety and prioritization of interventions and provide a summary of the emerging therapeutic approaches.Recent findingsDuring the past few years, high-quality randomized controlled t...
Source: Current Treatment Options in Neurology - March 17, 2020 Category: Neurology Source Type: research

A case of tardive dyskinesia (td) in a patient with non squamous cell carcinoma being treated with aripiprazole
Aripiprazole is an atypical antipsychotic that is usually well tolerated. It is FDA approved for treatment for schizophrenia and mania in Bipolar Disorder. Off label use includes augmentation protocols for depression and anxiety disorders as well as aggression in the pediatric population. Properties include 5-HT1A partial agonism and 5HT1-A antagonism along with D2 and D3 agonism. Abilify is often preferred due to reduced risk of metabolic syndrome, extrapyramidal symptoms and minimal sedative profile. (Source: The American Journal of Geriatric Psychiatry)
Source: The American Journal of Geriatric Psychiatry - March 14, 2020 Category: Geriatrics Authors: Ashish Sarangi Tags: Poster Number: EI-51 Source Type: research

Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I Disorder.
Authors: Kuo J, Lin SK Abstract Extended-release injectable (ERI) aripiprazole is indicated for schizophrenia and maintenance monotherapy of bipolar I disorder. Clinical trials of aripiprazole failed to exhibit efficacy in the treatment of bipolar depression. It has been suggested that relatively high doses, rapid titration of dose, a high dropout rate, and a high placebo effect might be the reasons of its ineffectiveness. Here, we report a case of a 39-year-old woman with bipolar depression who was successfully treated with ERI aripiprazole. PMID: 32148990 [PubMed] (Source: Case Reports in Psychiatry)
Source: Case Reports in Psychiatry - March 11, 2020 Category: Psychiatry Tags: Case Rep Psychiatry Source Type: research

Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease.
CONCLUSIONS: Inappropriate AAP use is associated with a higher risk of all-cause-mortality in older patients with PD which is mainly mediated by pneumonia. Therefore, inappropriate AAP use should be avoided to improve quality of care in PD. PMID: 32147383 [PubMed - as supplied by publisher] (Source: The American Journal of Geriatric Psychiatry)
Source: The American Journal of Geriatric Psychiatry - March 11, 2020 Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research

Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the Prophylaxis of Bipolar Disorder Type I with Manic Predominance
The objective of this study was the evaluation of utility of plasma level monitoring in the clinical stabilizing efficacy and tolerability of paliperidone palmitate (PP) vs. aripiprazole monohydrate (AM) in bipolar disorder I (BD I) with manic predominance. Methods Fifty-six outpatients of both sexes, age ranging from 18 to 65 years, affected by BD I with manic predominance, orally treated and stabilized after acute episode for at least 2 weeks with paliperidone or aripiprazole (n=31, paliperidone; n=25, aripiprazole) underwent a prospective observational study of switching to the corresponding long-acting injection (LAI) ...
Source: Pharmacopsychiatry - March 10, 2020 Category: Psychiatry Authors: Mauri, Massimo Carlo Reggiori, Alessandra Minutillo, Alessandro Franco, Gemma Pace, Chiara Di Paletta, Silvia Cattaneo, Dario Tags: Original Paper Source Type: research

Long-acting injectable vs oral antipsychotics: Adherence, persistence and switching over three years of real-life analysis.
CONCLUSIONS: In all drugs of the present study, adherence values were better in LAI than in OA, whereas no statistically significant difference was found in persistence values. PMID: 32148198 [PubMed - as supplied by publisher] (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - March 9, 2020 Category: Drugs & Pharmacology Authors: Romagnoli A, Santoleri F, Costantini A Tags: Curr Clin Pharmacol Source Type: research

Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study.
Conclusions: In comparison with the previous oral treatment with SGAs, patients showed a significant improvement in neurocognitive function after 12 months of treatment with SGA-LAI. Furthermore, there were no differences between the SGA-LAI regimens.Key pointsThe main purpose of this study was to assess possible modification of cognitive performance of patients with Schizophrenia treated with second generation long-acting injectable antipsychotics (SGA-LAIs).The secondary objective was to carry out a head to head comparison of two different SGA-LAIs: Paliperidone Palmitate 1-Month (PP1M) and Aripiprazole Monthly (A...
Source: International Journal of Psychiatry in Clinical Practice - March 7, 2020 Category: Psychiatry Tags: Int J Psychiatry Clin Pract Source Type: research

Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials
Conclusions All medications studied in bipolar disorder were relatively well tolerated during different phases of treatment; however, the risk for short- and long-term WG and somnolence varied widely among included psychotropics. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - March 1, 2020 Category: Psychiatry Tags: Review Articles Source Type: research

Problem Gambling Associated With Aripiprazole in First-Episode Psychosis Patients: A Series of 6 Case Reports
This article describes 6 cases with first-episode psychosis in whom PBG emerged while on ARI. Detailed information was gathered from clinical staff and patients' families to systematically assess the causal link between ARI and the emergence of PBG using the Naranjo and Liverpool Adverse Drug Reaction scales. Findings Five of these cases were previously diagnosed with a substance use disorder and/or cluster B personality traits. Five had received a more potent dopaminergic antagonist treatment before being switched to ARI. Two of them had presented PBG before being diagnosed with a psychotic disorder. The level of certa...
Source: Journal of Clinical Psychopharmacology - March 1, 2020 Category: Psychiatry Tags: Brief Reports Source Type: research

Serum Aripiprazole Concentrations Prehemodialysis and Posthemodialysis in a Schizophrenic Patient With Chronic Renal Failure: A Case Report
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - March 1, 2020 Category: Psychiatry Tags: Letters to the Editors — Case Reports Source Type: research

Adult Mild Encephalitis With Reversible Splenial Lesion Associated With Delirious Mania: A Case Report
Mild encephalitis with reversible splenial lesion is a rare clinic-radiological entity presenting with neurological and neuropsychiatric symptoms associated with cerebral lesion/s. Delirious mania is a severe psychiatric syndrome characterized by acute onset of delirium, excitement, and psychosis with a high mortality rate. In this paper, we present a case report of mild encephalitis with reversible splenial lesion clinically presenting as delirious mania and evolving into life-threatening multi-organ failure. The patient was treated with aripiprazole and benzodiazepine with poor effect and, after 4 days, the patient's con...
Source: Frontiers in Psychiatry - February 26, 2020 Category: Psychiatry Source Type: research

The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index
In this non-interventional study, the functionality and well-being of patients with schizophrenia with aripiprazole once-monthly (AOM) was evaluated under real-life conditions in a naturalistic population. (Source: BMC Psychiatry)
Source: BMC Psychiatry - February 22, 2020 Category: Psychiatry Authors: Daniel Sch öttle, Wolfgang Janetzky, Daniel Luedecke, Elmar Beck, Christoph U. Correll and Klaus Wiedemann Tags: Research article Source Type: research

A Case of Comorbid PTSD and Posttraumatic OCD Treated with Sertraline-Aripiprazole Augmentation.
Authors: Rossi R, Niolu C, Siracusano A, Rossi A, Di Lorenzo G Abstract Several studies report on traumatic history in Obsessive Compulsive Disorder (OCD) and comorbidity between Posttraumatic Stress Disorder (PTSD) and OCD. First-line pharmacological treatments for both OCD and PTSD are primarily based on antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Noradrenaline Reuptake Inhibitors (SNRI) such as Venlafaxine for PTSD. Second-Generation Antipsychotic (SGA) augmentation has shown good outcomes for nonresponsive OCD cases. However, evidence on the use of SGA in PTSD is mor...
Source: Case Reports in Psychiatry - February 14, 2020 Category: Psychiatry Tags: Case Rep Psychiatry Source Type: research

Antipsychotics for Treatment of Adolescent Onset Schizophrenia: a Review
This article reviews the pharmacological treatment of adolescents with schizophrenia, when possible, with a focus on the past five years of research.Recent FindingsThere are relatively few randomized controlled trials (RCTs) and head-to-head trials informing selection of a medication in pediatric schizophrenia. However, recent literature focusing on the efficacy and tolerability of atypical antipsychotics has led to the Food and Drug Administration (FDA) approval of multiple agents, specifically risperidone, olanzapine, quetiapine, aripiprazole, paliperidone, and lurasidone, for the treatment of pediatric schizophreni...
Source: Current Treatment Options in Psychiatry - February 14, 2020 Category: Psychiatry Source Type: research

Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders
Publication date: April 2020Source: Research in Autism Spectrum Disorders, Volume 72Author(s): Selma Tural Hesapcioglu, Mehmet Fatih Ceylan, Meryem Kasak, Cansu Pınar SenAbstractBackgroundThe aim of this study is to examine the use of olanzapine, risperidone and aripiprazole in autism spectrum disorders (ASD) in terms of their effects and side effects.MethodsASD patients that had been initiated to be treated with one of the three antipsychotics that continued for a minimum of eight weeks were included in the study, retrospectively. The participants were recruited with 20 olanzapine using patients (2.5−10 mg/day) in ...
Source: Research in Autism Spectrum Disorders - February 8, 2020 Category: Psychiatry Source Type: research

Design and Evaluation of a SelfEmulsifying Drug Delivery System of Aripiprazole
A. R. Ramya, Preethi Sudheer*, A. S. Mohameid and A. K. Das (Source: Indian Journal of Pharmaceutical Sciences)
Source: Indian Journal of Pharmaceutical Sciences - February 8, 2020 Category: Drugs & Pharmacology Source Type: research

Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models.
Authors: Jovanović M, Vučićević K, Miljković B Abstract Antipsychotic medicines are widely used for the management of psychotic symptoms regardless of the underlying diagnosis. Most atypical antipsychotics undergo extensive metabolism prior to excretion. Various factors may influence their pharmacokinetics, particularly elimination, leading to highly variable drug concentrations between individual patients following the same dosing regimen. Population pharmacokinetic approach, based on nonlinear mixed effects modeling, is a useful tool to identify covariates explaining pharmacokinetic variability, as well as t...
Source: Drug Metabolism Reviews - February 6, 2020 Category: Drugs & Pharmacology Tags: Drug Metab Rev Source Type: research

Treatment of Mixed Features in Bipolar Disorder: an Updated View
AbstractPurpose of ReviewMixed presentations in bipolar disorder have long posed clinical and nosological challenges. The DSM-5 mixed features specifier was developed to provide a more flexible and clinically relevant definition of mixed presentations compared with narrowly defined DSM-IV mixed episodes. However, there is little guidance on treating such presentations. Here, we summarize the evidence for biological treatments of DSM-5 and similarly defined mixed features (MFs).Recent FindingsThe literature on treating MFs is almost exclusively based on post hoc analyses. Within this limited evidence base is preliminary pos...
Source: Current Psychiatry Reports - February 6, 2020 Category: Psychiatry Source Type: research

When to Raise Our White Flag—A Discussion of Scope of Practice in a Resource Scarce World
CASE: Thomas is a 13-year-old boy with autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), generalized anxiety disorder, separation anxiety disorder, and major depressive disorder who presented for a follow-up to his developmental and behavioral pediatrician (DBP). His mother describes an increase in symptoms of anxiety and depression for the last 6 weeks, accompanied by suicidal ideation and thoughts of self-mutilation. Before this increase in symptoms, he had been doing well for the last several months with the exception of increasing weight gain, and Abilify was decreased from 5 mg to 2.5 mg at...
Source: Journal of Developmental and Behavioral Pediatrics - February 1, 2020 Category: Child Development Tags: Challenging Case Source Type: research

Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series.
Conclusions: Hyperprolactinemia is frequently observed in patients treated with antipsychotic medications. Low-dose treatment with aripiprazole may offer a relatively rapid relief from sustained hyperprolactinemia and associated adverse effects even after a long-acting injectable is discontinued. PMID: 31999895 [PubMed - in process] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - January 31, 2020 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research

[ASAP] Application of the Method of Molecular Voronoi –Dirichlet Polyhedra for Analysis of Noncovalent Interactions in Aripiprazole Polymorphs
Crystal Growth& DesignDOI: 10.1021/acs.cgd.9b01645 (Source: Crystal Growth and Design)
Source: Crystal Growth and Design - January 31, 2020 Category: Chemistry Authors: Viktor N. Serezhkin* and Anton V. Savchenkov Source Type: research

Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis
ConclusionsDifferences in short-term efficacy and safety for acute schizophrenia were not apparent between aripiprazole and brexpiprazole. Future studies are warranted to evaluate whether there are differences in the long-term outcome between treatments. (Source: Psychopharmacology)
Source: Psychopharmacology - January 30, 2020 Category: Psychiatry Source Type: research

1-(Benzo[b]thiophen-4-yl)piperazine Ring Induced Bioactivation of Brexpiprazole in Liver Microsomes: Identification and Characterization of Reactive Conjugates Using Ultra-High-Performance Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry
ConclusionBrexpirazole is bioactivated due to the presence of a 1-(benzo[b]thiophen-4-yl)piperazine ring in its structure. In contrast to aripiprazole, the quinolinone motif was found latent towards bioactivation  in brexpiprazole. (Source: European Journal of Drug Metabolism and Pharmacokinetics)
Source: European Journal of Drug Metabolism and Pharmacokinetics - January 30, 2020 Category: Drugs & Pharmacology Source Type: research

Design and Evaluation of a SelfEmulsifying Drug Delivery System of Aripiprazole
A. R. Ramya, Preethi Sudheer*, A. S. Mohameid and A. K. Das (Source: Indian Journal of Pharmaceutical Sciences)
Source: Indian Journal of Pharmaceutical Sciences - January 21, 2020 Category: Drugs & Pharmacology Source Type: research

Drugs for Depression
Date: February 24, 2020 Issue #:  1592Summary:  Complete remission of symptoms is the goal of treatment for major depressive disorder; a partial response is associated with an increased risk of relapse. Improvement in symptoms can occur within the first two weeks of treatment with an antidepressant, but it may take 4-8 weeks to achieve a substantial benefit. Following successful treatment of a first major depressive episode, antidepressant treatment should be continued at the same dose for at least 4-9 months to consolidate recovery. In patients with recurrent depressive episodes, long-term mai...
Source: The Medical Letter - January 17, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Abilify Amitriptyline Amoxapine Antidepressants Antipsychotics aplenzin Aripiprazole Aventyl brexanolone brexpiprazole Bupropion BuSpar Buspirone Celexa Cipralex Citalopram Cymbalta Deep Brain stimulation Deplin Depre Source Type: research

Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
Authors: García Álvarez JC, González Sánchez L, García Resa E, Bonete Llácer JM, Román Rodríguez A, Pecino Esquerdo B, Pérez Martínez E Abstract Objective: To evaluate the effectiveness of 6-month treatment with aripiprazole long-acting injectable (LAI) in improving psychotic symptoms, social functioning and side effects and reducing co-administered antipsychotic drugs.Methods: Multicentre, observational, prospective study that enrolled 53 patients with diagnosis of schizophrenia spectrum disorders who initiated or switched to aripiprazole LAI. T...
Source: International Journal of Psychiatry in Clinical Practice - January 16, 2020 Category: Psychiatry Tags: Int J Psychiatry Clin Pract Source Type: research

Memory deterioration based on the tobacco smoke exposure and methylazoxymethanol acetate administration vs. aripiprazole, olanzapine and enrichment environment conditions
Publication date: Available online 15 January 2020Source: Pharmacology Biochemistry and BehaviorAuthor(s): Ratajczak Piotr, Kus Krzysztof, Murawiecka Patrycja, Słodzińska Iwona, Zaprutko Tomasz, Kopciuch Dorota, Paczkowska Anna, Nowakowska ElżbietaAbstractEnrichment environment conditions, as well as tobacco smoke exposure, may affect cognitive function (e.g. spatial memory) in an animal model of schizophrenia and schizophrenic patients.The aim of this study was to find whether spatial memory function impairment is found in methylazoxymethanol acetate treated rats (an animal model of schizophrenia) and whether aripipraz...
Source: Pharmacology Biochemistry and Behavior - January 15, 2020 Category: Biochemistry Source Type: research

An investigation of cortical thickness and antidepressant response in major depressive disorder: a CAN-BIND study report
Publication date: Available online 13 January 2020Source: NeuroImage: ClinicalAuthor(s): Jee Su Suh, Luciano Minuzzi, Pradeep Reddy Raamana, Andrew Davis, Geoffrey B. Hall, Jacqueline Harris, Stefanie Hassel, Mojdeh Zamyadi, Stephen R. Arnott, Gésine L. Alders, Roberto B. Sassi, Roumen Milev, Raymond W. Lam, Glenda M. MacQueen, Stephen C. Strother, Sidney H. Kennedy, Benicio N. FreyAbstractMajor depressive disorder (MDD) is considered a highly heterogeneous clinical and neurobiological mental disorder. We employed a novel layered treatment design to investigate whether cortical thickness features at baseline differe...
Source: NeuroImage: Clinical - January 15, 2020 Category: Radiology Source Type: research

Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial.
Abstract Antipsychotics are used for many psychiatric conditions in youth. Although developmentally inappropriate weight gain and metabolic abnormalities, which are risk factors for premature cardiovascular mortality, are especially frequent in youth, optimal strategies to reduce pediatric antipsychotic-induced overweight/obesity are unclear. The Improving Metabolic Parameters in Antipsychotic Child Treatment (IMPACT) was a randomized, parallel group, 24-week clinical trial which enrolled overweight/obese, psychiatrically stable youth, aged 8-19 years, with a DSM-IV diagnosis of severe mental illness (schizop...
Source: World Psychiatry - January 12, 2020 Category: Psychiatry Authors: Correll CU, Sikich L, Reeves G, Johnson J, Keeton C, Spanos M, Kapoor S, Bussell K, Miller L, Chandrasekhar T, Sheridan EM, Pirmohamed S, Reinblatt SP, Alderman C, Scheer A, Borner I, Bethea TC, Edwards S, Hamer RM, Riddle MA Tags: World Psychiatry Source Type: research

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine.
Authors: Luykx JJ, Stam N, Tanskanen A, Tiihonen J, Taipale H Abstract BACKGROUND: Although clozapine is often discontinued, there is a paucity of guidelines and evidence on treatment options after clozapine discontinuation. Moreover, it is currently unknown whether reinstating clozapine in patients formerly using clozapine should be avoided. AIMS: To compare the real-world effectiveness of antipsychotics after clozapine cessation. METHOD: From Finnish registry data (1995-2017), we identified 2250 patients with schizophrenia who had been using clozapine for ≥1 year before treatment cessation. The primary...
Source: The British Journal of Psychiatry for Mental Science - January 9, 2020 Category: Psychiatry Tags: Br J Psychiatry Source Type: research

Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
This study compared all-cause and psychiatric inpatient hospitalization and medical costs in adult patients with SCZ newly treated with brexpiprazole versus other US Food and Drug Administration-approved OAAs in a real-world setting. METHODS: This retrospective cohort study analyzed data from: (1) the IBM MarketScan Commercial and Medicare Supplemental databases, and the MarketScan Multi-State Medicaid database; and (2) the de-identified Optum Clinformatics Datamart. Adult patients were identified if they had SCZ and initiated either brexpiprazole or another OAA during the study identification period (July 1, 2015, to...
Source: Clinical Therapeutics - January 9, 2020 Category: Drugs & Pharmacology Authors: Yan T, Greene M, Chang E, Houle CR, Waters HC, Tarbox MH, Broder MS Tags: Clin Ther Source Type: research

Aripiprazole Long-Acting Injection During First Episode Schizophrenia —An Exploratory Analysis
Background: Long-acting injectable (LAI) aripiprazole was found to be efficacious in schizophrenia. In common clinical practice, the use of LAIs is often restricted to chronic patients with frequent relapses and poor adherence. Recently, some investigators advanced the idea of early LAI use also in young people with schizophrenia at their first psychotic episode (FEP).Objective: Our study aimed to assess the effect of LAI aripiprazole once monthly (AOM) in the treatment of FEP in patients aged 18–26 years.Methods: We included 50 patients with DSM-5 schizophrenia as assessed with SCID, and used the Clinical Global Imp...
Source: Frontiers in Psychiatry - January 8, 2020 Category: Psychiatry Source Type: research

Mortality Risk Associated with Haloperidol Use Compared with Other Antipsychotics: An 11-Year Population-Based Propensity-Score-Matched Cohort Study
ConclusionHaloperidol was associated with increased overall mortality when compared with other antipsychotics in long-term follow-up. Treatment with haloperidol should be carefully considered, especially in older patients and patients at risk of CVD or pneumonia, since the risk of death appears to be lower with non-haloperidol agents. (Source: CNS Drugs)
Source: CNS Drugs - January 8, 2020 Category: Neurology Source Type: research

Aripiprazole for prevention of delirium in the neurosurgical intensive care unit: a double-blind, randomized, placebo-controlled study
ConclusionsAripiprazole can reduce the incidence of delirium in the neurosurgical ICU. Studies with larger sample size in diverse ICU settings and longer follow-up are needed to confirm our findings. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - January 3, 2020 Category: Drugs & Pharmacology Source Type: research

AJP Articles Named ‘Top Stories of 2019’ By NEJM Journal Watch Psychiatry
Two articles published last year in theAmerican Journal of Psychiatry have been named “top stories of 2019” by the editorial board ofNEJM Journal Watch Psychiatry.“As always, we looked for high clinical relevance, balanced with solid methodology, and every study we chose focused on improving clinicians' abilities to treat patients, whether by identifying the best options or highlighting the weaknesses of some once-touted approaches,” wrote Peter Roy-Byrne , M.D., editor-in-chief ofNEJM Journal Watch Psychiatry, in a post announcing the selection of top journal articles of the year. These are theAJP ...
Source: Psychiatr News - January 2, 2020 Category: Psychiatry Tags: AJP anorexia nervosa Evelyn Attia NEJM Journal Watch Psychiatry olanzapine Peter Roy-Byrne Sidney Zisook treatment-resistant depression VAST-D Source Type: research

Aripiprazole prevents stress-induced anxiety and social impairment, but impairs antipredatory behavior in zebrafish
Publication date: Available online 29 December 2019Source: Pharmacology Biochemistry and BehaviorAuthor(s): Heloísa Helena de Alcantara Barcellos, Aline Pompermaier, Suelen Mendonça Soares, Victoria Costa Maffi, Marina Fernandes, Gessi Koakoski, Karina Kirsten, Bernardo Baldisserotto, Leonardo José Gil BarcellosAbstractEnvironmental pollution caused by antipsychotic residues is a relevant ecological problem. Studies revealed that residues of these drugs are present in a wide range of different ecosystems and can have adverse effects on non-target organisms even in low environmental concentrations. Amon...
Source: Pharmacology Biochemistry and Behavior - December 29, 2019 Category: Biochemistry Source Type: research

Segmental analysis of antidepressant and antipsychotic drugs in the hair of schizophrenic patients
AbstractHair analysis is useful for documenting long ‐term exposure to drugs. The potential of hair analysis for therapeutic drug monitoring within the forensic field has been studied, but reference values for some antidepressants and antipsychotics in the hair of individuals undergoing chronic therapy are still lacking. In the present study, a meth od was developed and validated for the determination of 23 analytes, including antidepressants, antipsychotics and related metabolites, in human hair by liquid chromatography–tandem mass spectrometry (LC–MS/MS). Hair samples (10 mg) were extracted with a 25:25:50 ...
Source: Drug Testing and Analysis - December 25, 2019 Category: Drugs & Pharmacology Authors: Xin Wang, Yue Zhuo, Xiaowei Tang, Huosheng Qiang, Wei Liu, Hejian Wu, Ping Xiang, Gengli Duan, Min Shen Tags: RESEARCH ARTICLE Source Type: research

Pisa Syndrome and Aripiprazole
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - December 24, 2019 Category: Psychiatry Tags: Letters to the Editors Source Type: research

Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy
Conclusions The present study suggests that ARP lowers serum PRL levels regardless of monopharamacy or polypharmacy with antipsychotics. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - December 24, 2019 Category: Psychiatry Tags: Original Contributions Source Type: research

Orodispersible Films Containing Ball Milled Aripiprazole-Poloxamer®407 Solid Dispersions
Publication date: Available online 13 December 2019Source: International Journal of PharmaceuticsAuthor(s): Ewelina Łyszczarz, Justyna Hofmanová, Joanna Szafraniec-Szczęsny, Renata JachowiczAbstractThis research aimed at developing ODFs containing an antipsychotic drug – aripiprazole (ARP). ARP, as a BCS II class molecule, requires enhancing its water solubility prior to formulating. Therefore, a solid dispersion of ARP – Poloxamer® 407 was prepared by ball milling then incorporated into the films. It was found that co-processing led to an over 100-fold increase in drug solubility in comparison wit...
Source: International Journal of Pharmaceutics - December 18, 2019 Category: Drugs & Pharmacology Source Type: research

Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis
We examined the association between metabolic change and psychopathology change by estimating the correlation between symptom severity change and metabolic parameter change.FindingsOf 6532 citations, we included 100 randomised controlled trials, including 25 952 patients. Median treatment duration was 6 weeks (IQR 6–8). Mean differences for weight gain compared with placebo ranged from −0·23 kg (95% CI −0·83 to 0·36) for haloperidol to 3·01 kg (1·78 to 4·24) for clozapine; for BMI from −0·25 kg/m2 (−0·68 to 0·17) for haloperidol ...
Source: The Lancet Psychiatry - December 18, 2019 Category: Psychiatry Source Type: research

Meta-Analysis Identifies Effective Doses and Dose Equivalents for 20 Antipsychotics
Ameta-analysis published today inAJP in Advance reports the maximum effective dose for 20 antipsychotic medications, including both oral and long-acting injectable (LAI) formulations. The report also included the authors ’ calculations of the dose equivalents of these 20 medications.“The dose-response relationships of antipsychotic drugs for the acute treatment of schizophrenia are not well understood, but further defining them would be important for many reasons,” wrote Stefan Leucht, M.D., of the Technical University of Munich and colleagues. “Clinicians need to know th e minimum effective doses a...
Source: Psychiatr News - December 16, 2019 Category: Psychiatry Tags: antipsychotic aripiprazole dosage dose equivalent dose response long-acting injectable lurasidone meta-analysis olanzapine risperidone schizophrenia Source Type: research

Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
CONCLUSIONS: In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy. For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau. PMID: 31838873 [PubMed - as supplied by publisher] (Source: The American Journal of Psychiatry)
Source: The American Journal of Psychiatry - December 16, 2019 Category: Psychiatry Authors: Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM Tags: Am J Psychiatry Source Type: research

Efficacy of aripiprazole in severe, persistent, socially- and occupationally-impairing developmental stuttering.
Authors: Bharadwaj A, Andrade C PMID: 31812095 [PubMed - as supplied by publisher] (Source: Asian Journal of Psychiatry)
Source: Asian Journal of Psychiatry - December 9, 2019 Category: Psychiatry Tags: Asian J Psychiatr Source Type: research

Use of cardiovascular and antidiabetic drugs before and after starting with clozapine versus other antipsychotic drugs: a Dutch database study
Reports of decreased mortality among patients with schizophrenia who use clozapine may be biased if clozapine is prescribed to relatively healthy patients and if intensive monitoring during its use prevents (under-treatment of) somatic disorder. We aimed to assess whether there is a difference in: (1) somatic comorbidity between patients who start with clozapine and those who start with other antipsychotics and (2) prescribed somatic medication, between patients using clozapine and those using olanzapine. Cohort study based on insurance claims (2010–2015). After selecting new users of antipsychotics and those who sub...
Source: International Clinical Psychopharmacology - December 3, 2019 Category: Psychiatry Tags: Original Articles Source Type: research

Optimized Treatment Strategy for Depressive Disorder.
Authors: Chen P Abstract Despite many advances in pharmacotherapy over the past half centurye, only a fraction of patients with Major Depressive Disorder (MDD) can achieve remission after the first or second trial of pharmacotherapy. Those who failed standard antidepressant treatment are termed as Treatment-Resistant Depression (TRD). Pharmacotherapy for TRD is more viable over past 15 years in part due to advances in clinical trials such as the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) and the US Department of Veterans Affairs Augmentation and Switching Treatments for Improving Depressio...
Source: Advances in Experimental Medicine and Biology - December 2, 2019 Category: Research Tags: Adv Exp Med Biol Source Type: research